Respiratory Function in Patients With Post-tuberculosis Lung Impairment

Sponsor
Università degli Studi dell'Insubria (Other)
Overall Status
Unknown status
CT.gov ID
NCT03821285
Collaborator
Fondazione Salvatore Maugeri (Other), Azienda Ospedaliero Universitaria di Sassari (Other), Instituto Nacional de Enfermedades Respiratorias (Other)
100
1
1
23
4.3

Study Details

Study Description

Brief Summary

Pulmonary tuberculosis (TB) is an important risk factor for chronic respiratory disease due to residual lung damage. A recent review of the literature on TB sequelae and rehabilitation has provided clear evidence that TB is definitively responsible for lung function impairment. Functional evaluation of TB patients after completion of pulmonary tuberculosis treatment or spontaneous healing should be considered as part of clinical care. Unfortunately, few studies are available in the literature investigating the physiopathology of lung damage, its impact on quality of life, the potential need for pulmonary rehabilitation (PR), and the effects of a PR program.Objectives of this prospective multicentre international study are: Primary Objective-to assess the exercise capacity 6-min walking test in patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment or after spontaneous healing. Secondary Objectives-to assess the effects of the PR program on dyspnoea symptoms and muscle fatigue, quality of life.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pulmonary Rehabilitation
N/A

Detailed Description

Methods Respiratory functional parameters at baseline and at the end of the 15 sessions rehabilitation programme (RP) will be collected at the participating Centre. Follow-up visit 1 year after completion of RP Baseline assessment

  1. After signature of the informed consent to the study, patients will undergo a Pre-screening Visit: data on medical history, current pharmacological therapies, smoking (pack/year), vaccinations, physical examination, vital parameters (blood pressure, heart rate, respiratory rate, oxygen saturation in arterial blood), co-morbidities and Mini Mental State Examination will be collected.

  2. Screening Visit (before the RP), during the visit the following data will be collected: number of TB disease episodes, detailed data on the last TB episode (age at onset of TB symptoms, age at TB diagnosis, anti-TB treatment duration, anti-TB drugs administered, socio-economic conditions, education level, physical examination, vital parameters, oxygen saturation in arterial blood, heart rate and respiratory rate). Pulmonary rehabilitation program tailored according to specific patient's needs.

  3. Baseline assessment of respiratory function: arterial blood gas (ABG) analysis, spirometry, diffusing capacity of the lungs for carbon monoxide (DLCO), overnight oximetry, electrocardiogram (ECG), chest X-ray (CXR), High-resolution computed tomography (HRCT)

  4. Assessment of the rehabilitation programme: functional evaluation (6MWT), muscle strength evaluation (five-repetition sit-to-stand test (5STS)), respiratory muscle strength (maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)), symptoms evaluation (Dyspnea: Medical Research Council Questionnaire (MRC), Modified

Borg pre/post 6MWT, Baseline and Transition Dyspnea Indexes (BDI-TDI) and Fatigue:

Modified Borg pre/post 6MWT)

  1. Assessment of the Quality of Life (QoL): CAT and St George's Respiratory Questionnaire.
Final assessment:
A final assessment will be done at the end of the rehabilitation programme and will include:
  1. Only ABG, spirometry and DLCO d) and e).

Pulmonary rehabilitation programme

PR programme will include:

At least 15 aerobic-training sessions by cycle ergometer supervised by a respiratory therapist (5 session per week, 30 minutes each: 5 minutes warm up, 20 minutes training and 5 minutes warm-down) at constant load (calculated with Hill equation, Hill K, et al. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008;89(9):1782-7.) with an adherence of at least 80%.

  1. At least 15 strength-training sessions for peripheral muscles (30 minutes calisthenics exercise) with an adherence of at least 80%.

  2. At least 3 face to face and/or group educational sessions, for:

  • Optimization of inhalation techniques

  • Exercise training and maintenance programs

  • Daily physical activity

  • Airways clearance techniques

  • Long oxygen therapy home management.

  1. According to individual needs, the PR program should include:
  • airways clearance techniques

  • inspiratory muscles training (with Threshold®)

Monitoring Anonymous data will be collected in a common electronic format (excel database).

Adverse events (AEs) and severe adverse events (SAEs) will be reported and registered.

Follow-up

Follow-up visit 1 year after completion of RP will include:
  1. Only ABG, spirometry, DLCO and overnight oximetry d) and e) Statistical analysis A two-tailed p-value less than 0.05 will be considered statistically significant.

Qualitative and quantitative variables will be described with absolute and relative (percentages) frequencies and means (standard deviations -SD) or medians (interquartile ranges -IQR) depending on their normality, respectively. The mean difference between the two study groups in the 6MWT will be evaluated using the Student's t-test. Differences in the variables associated to the secondary objectives will be evaluated using the Chi-square or Student's t-test for qualitative and quantitative variables. A two-tailed p-value less than 0.05 will be considered statistically significant.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Prospective, multicentre internationalProspective, multicentre international
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Evaluation of Respiratory Function in Patients With Post-tuberculosis Lung Impairment After Pulmonary Tuberculosis Treatment or After Spontaneous Healing
Anticipated Study Start Date :
Feb 14, 2019
Anticipated Primary Completion Date :
Jul 31, 2020
Anticipated Study Completion Date :
Jan 14, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: pulmonary rehabilitation

Pulmonary rehabilitation program

Procedure: Pulmonary Rehabilitation
Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training

Outcome Measures

Primary Outcome Measures

  1. 6-min walking test [1 year]

    Exercise capacity

Secondary Outcome Measures

  1. dyspnoea [1 year]

    Modified BORG scale (0-10) 0 better, 10 worse

  2. muscle fatigue [1 year]

    Modified Borg scale (0-10) 0 better, 10 worse

  3. health related quality of life [1 year]

    st. George Respiratory Questionnaire 0 better, 100 worse

  4. health status [1 year]

    COPD Assessment test-CAT (0-40) 0 better, 40 worse

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment - Patients with post- TB impairment after spontaneous healing
Exclusion Criteria:
  • Any unstable medical condition

  • Musculoskeletal disorders contraindicating participation in the PR program

  • Cognitive impairment (Mini Mental State Examination <22)

  • Unable to sign informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 ICS Maugeri, IRCCS Tradate Varese Italy 21049

Sponsors and Collaborators

  • Università degli Studi dell'Insubria
  • Fondazione Salvatore Maugeri
  • Azienda Ospedaliero Universitaria di Sassari
  • Instituto Nacional de Enfermedades Respiratorias

Investigators

  • Study Director: Giovan Battista Migliori, Prof, ICS Maugeri, IRCCS

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dina Visca, Principal Investigator, Università degli Studi dell'Insubria
ClinicalTrials.gov Identifier:
NCT03821285
Other Study ID Numbers:
  • 2215CE
First Posted:
Jan 29, 2019
Last Update Posted:
Jan 29, 2019
Last Verified:
Jan 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dina Visca, Principal Investigator, Università degli Studi dell'Insubria
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 29, 2019